By admin 
In a significant move toward addressing one of the most challenging diagnoses in pediatric oncology, CureSearch for Children’s Cancer has announced a major funding initiative led by Dr. John Lee of the David Geffen School of Medicine at UCLA. This project, funded through the prestigious Acceleration Initiative Award, represents a $900,000 investment into the development of a novel immunotherapy designed specifically for metastatic Ewing sarcoma. By focusing on the enhancement of CAR T-cell therapy through the integration of Interleukin-18 (IL-18), Dr. Lee and his team are attempting to bridge the gap between laboratory discovery and clinical application for a patient population that currently faces a five-year survival rate as low as 15%.
The Clinical Challenge of Metastatic Ewing Sarcoma
Ewing sarcoma is the second most common bone cancer in children and young adults, characterized by its aggressive nature and propensity for early metastasis. While localized Ewing sarcoma has seen improvements in survival rates over the last several decades—climbing to approximately 70% to 80% with intensive chemotherapy, radiation, and surgery—the outlook for patients whose cancer has spread remains grim. Once the disease reaches the lungs, bone marrow, or other bones, the effectiveness of standard treatments drops precipitously.
The primary driver of Ewing sarcoma is typically a chromosomal translocation, most commonly the fusion of the EWS gene on chromosome 22 to the FLI1 gene on chromosome 11. This fusion protein acts as an aberrant transcription factor, driving the malignant transformation of cells. Despite knowing the genetic cause, targeting this protein directly has proven exceptionally difficult. Consequently, the medical community has turned its attention to immunotherapy, a field that has revolutionized the treatment of blood cancers like leukemia but has struggled to achieve similar results in solid tumors like sarcomas.
The Innovation: CAR T-Cell Therapy and the IL-18 "Supercharger"
Dr. John Lee’s research centers on Chimeric Antigen Receptor (CAR) T-cell therapy, a process where a patient’s own immune cells are harvested and genetically re-engineered to recognize and attack specific proteins on the surface of cancer cells. While CAR T-cell therapy has been a "miracle cure" for some pediatric B-cell leukemias, its application in Ewing sarcoma has been hindered by the immunosuppressive environment of solid tumors.
The "microenvironment" of a sarcoma often acts as a shield, preventing T-cells from penetrating the tumor or causing them to become "exhausted" before they can eliminate the cancer. To overcome this, Dr. Lee’s team is incorporating Interleukin-18 (IL-18) into the CAR T-cell design. IL-18 is a powerful cytokine—a signaling protein—that plays a crucial role in the innate and adaptive immune response.
By arming the CAR T-cells with the ability to secrete IL-18, the treatment does more than just attack the tumor directly; it effectively "broadcasts" a signal to the rest of the immune system. This cytokine secretion helps to modify the tumor microenvironment, making it more hospitable for immune activity and potentially recruiting other immune cells, such as Natural Killer (NK) cells, to join the fight. This multi-pronged approach is intended to ensure that the CAR T-cells remain active and potent long enough to eradicate metastatic lesions throughout the body.
Chronology of Development and the Acceleration Initiative
The timeline for this research is governed by the specific requirements of the CureSearch Acceleration Initiative. Unlike traditional academic grants that may fund basic science for a decade or more, the Acceleration Initiative is designed to fast-track projects that have a high probability of clinical application.
- Preclinical Phase (Current): Dr. Lee’s team is currently finalizing the preclinical models to demonstrate the efficacy and safety of the IL-18-enhanced CAR T-cells. This involves testing the therapy in advanced laboratory models that mimic the human metastatic environment.
- Regulatory Filing (Months 12-24): The project aims to move through the rigorous FDA Investigational New Drug (IND) application process. This requires detailed data on how the cells are manufactured and how they behave in biological systems.
- Clinical Trial Launch (Year 3): The ultimate goal of this $900,000 investment is to move the therapy into a Phase I clinical trial within three years. This would provide eligible children with metastatic Ewing sarcoma access to the treatment as part of a controlled study at UCLA and potentially other collaborating institutions.
This accelerated timeline is a response to the "valley of death" in drug development—the period where promising laboratory research often stalls due to a lack of funding for the expensive transition into human trials.
Supporting Data and the Need for Targeted Therapy
The urgency of Dr. Lee’s work is underscored by the toxicity of current standard-of-care treatments. Children with Ewing sarcoma often undergo high-dose chemotherapy regimens (such as VDC/IE) that carry significant long-term risks, including secondary cancers, heart failure, and infertility.
Data from the National Cancer Institute (NCI) indicates that while survival has improved for many pediatric cancers, the "tail of the curve" for metastatic bone sarcomas has remained stubbornly flat for nearly thirty years. Furthermore, Ewing sarcoma is known for its high rate of recurrence. Even patients who achieve initial remission face a high risk of the cancer returning in a more resistant form. Dr. Lee’s approach offers a more targeted alternative that could theoretically reduce the reliance on systemic toxins by utilizing the precision of the immune system.
Collaborative Funding and the Legacy of Patients
The funding for Dr. Lee’s research is the result of a collaborative co-funding model that brings together non-profit organizations and grieving families who have turned their personal loss into a catalyst for scientific progress. The Rally Foundation for Childhood Cancer Research has partnered with CureSearch to provide a portion of the award.
Crucially, the project is supported by three CureSearch Legacy Funds, which are established by families in memory of children who lost their battles with cancer. These include:
- The Garret Collins Legacy Fund: Established to honor Garret, whose journey inspired a mission to find less toxic treatments.
- The Nick Currey Fund: Founded by the family of Nick Currey, who emphasized the need for targeted therapies that might have saved his life had they been available a decade ago.
- The Sam Schneider Legacy: Created in memory of Sam Schneider, whose family has been vocal about the dangers of late detection in metastatic cases.
The Schneider family noted the frequent tragedy of Ewing sarcoma: "Sam’s cancer was detected well past becoming metastatic, which is so common for Ewing’s patients." This sentiment is echoed by Nick Currey’s family, who stated, "If more targeted, less toxic therapies had been available, Nick might be alive today."
Institutional Impact and Professional Analysis
The selection of Dr. John Lee, an associate professor in residence in the Division of Hematology/Oncology at the David Geffen School of Medicine at UCLA, reflects a strategic choice to invest in a hub of biotechnological innovation. UCLA’s infrastructure for cell manufacturing and its proximity to a diverse patient population make it an ideal site for a project of this magnitude.
From a broader oncological perspective, this research holds implications beyond Ewing sarcoma. If the addition of IL-18 is proven to successfully "uncloak" solid tumors for CAR T-cell attack, this platform could be adapted for other pediatric solid tumors, such as osteosarcoma or neuroblastoma. This "platform potential" is a key reason why the Acceleration Initiative selected this project for such a substantial grant.
The move toward "off-the-shelf" or highly potent "living drugs" represents the next frontier in medicine. However, the complexity of manufacturing these cells remains a hurdle. Part of the funded research will likely address the scalability of producing IL-18-enhanced CAR T-cells to ensure that once the trial begins, it can be expanded to accommodate more patients.
Future Outlook: A New Standard of Care?
While the research is currently in the preclinical stage, the medical community views this as a high-stakes, high-reward endeavor. If the three-year goal is met, it will represent one of the fastest transitions from a novel concept to a pediatric clinical trial in the field of sarcoma research.
For the families of children currently diagnosed with metastatic disease, the news provides a measure of hope where little previously existed. The commitment of over $900,000 ensures that Dr. Lee’s team has the resources to bypass the traditional delays of federal grant cycles. As the project progresses toward its 2027 clinical target, the focus will remain on the safety of the IL-18 secretion and the durability of the immune response in the face of a notoriously resilient cancer.
The success of this initiative will be measured not just in laboratory milestones, but in the survival statistics of the next generation of children diagnosed with Ewing sarcoma. By strengthening the immune system’s ability to defeat cancer cells, Dr. Lee’s research aims to turn a devastating prognosis into a manageable, and ultimately curable, condition.
